相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lecanemab in Early Alzheimer's Disease
Christopher H. van Dyck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Disease Modeling and Model-Based Meta-Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer's Disease
Sylvie Retout et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
Aducanumab Therapy to Treat Alzheimer’s Disease: A Narrative Review
Semira Abdi Beshir et al.
International Journal of Alzheimer's Disease (2022)
2021 Alzheimer's disease facts and figures
[Anonymous]
ALZHEIMERS & DEMENTIA (2021)
Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab
Gregory Klein et al.
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE (2021)
Brain Shuttle Neprilysin reduces central Amyloid-β levels
Christopher R. Campos et al.
PLOS ONE (2020)
Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys
Mihalis S. Kariolis et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Current and Future Treatments in Alzheimer Disease: An Update
Konstantina G. Yiannopoulou et al.
JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE (2020)
Present Algorithms and Future Treatments for Alzheimer's Disease
George T. Grossberg et al.
JOURNAL OF ALZHEIMERS DISEASE (2019)
The US Food and Drug Administration's Model-Informed Drug Development Paired Meeting Pilot Program: Early Experience and Impact
Rajanikanth Madabushi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Targeting the transferrin receptor for brain drug delivery
Kasper Bendix Johnsen et al.
PROGRESS IN NEUROBIOLOGY (2019)
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis
Gregory Klein et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
Impact of Reference and Target Region Selection on Amyloid PET SUV Ratios in the Phase 1b PRIME Study of Aducanumab
Ping Chiao et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Endosomal trafficking regulates receptor-mediated transcytosis of antibodies across the blood brain barrier
Arsalan S. Haqqani et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2018)
Antibody pharmacokinetics in rat brain determined using microdialysis
Hsueh-Yuan Chang et al.
MABS (2018)
Brain Shuttle Antibody for Alzheimer's Disease with Attenuated Peripheral Effector Function due to an Inverted Binding Mode
Felix Weber et al.
CELL REPORTS (2018)
Brain and Organ Uptake in the Rhesus Monkey in Vivo of Recombinant Iduronidase Compared to an Insulin Receptor Antibody-Iduronidase Fusion Protein
Ruben J. Boado et al.
MOLECULAR PHARMACEUTICS (2017)
Antibody therapies in CNS diseases
Per-Ola Freskgard et al.
NEUROPHARMACOLOGY (2017)
Sorting Tubules Regulate Blood-Brain Barrier Transcytosis
Roberto Villasenor et al.
CELL REPORTS (2017)
Potent and Selective BACE-1 Peptide Inhibitors Lower Brain Aβ Levels Mediated by Brain Shuttle Transport
Nadine Ruderisch et al.
EBIOMEDICINE (2017)
Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development
Jing Wang et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2016)
Mathematical PKPD and safety model of bispecific TfR/BACE1 antibodies for the optimization of antibody uptake in brain
Kapil Gadkar et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2016)
CSF, blood-brain barrier, and brain drug delivery
William M. Pardridge
EXPERT OPINION ON DRUG DELIVERY (2016)
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease
Jeff Sevigny et al.
NATURE (2016)
Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies
Y. Joy Yu Zuchero et al.
NEURON (2016)
Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
Tilman Schlothauer et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2016)
Trafficking of Endogenous Immunoglobulins by Endothelial Cells at the Blood-Brain Barrier
Roberto Villasenor et al.
SCIENTIFIC REPORTS (2016)
Prospective Design of Anti-Transferrin Receptor Bispecific Antibodies for Optimal Delivery into the Human Brain
J. S. Kanodia et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2016)
Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle
Jens Niewoehner et al.
NEURON (2014)
Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
Y. Joy Yu et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
The rights and wrongs of blood-brain barrier permeability studies: a walk through 100 years of history
Norman R. Saunders et al.
FRONTIERS IN NEUROSCIENCE (2014)
Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier
Jessica A. Couch et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Profile of gantenerumab and its potential in the treatment of Alzheimer's disease
Dijana Novakovic et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2013)
Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab
Susanne Ostrowitzki et al.
ARCHIVES OF NEUROLOGY (2012)
Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β
Bernd Bohrmann et al.
JOURNAL OF ALZHEIMERS DISEASE (2012)
Drug transport across the blood-brain barrier
William M. Pardridge
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2012)
Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data What have we learned?
Rong Deng et al.
MABS (2011)
The CNS microvascular pericyte: pericyte-astrocyte crosstalk in the regulation of tissue survival
Drew Bonkowski et al.
FLUIDS AND BARRIERS OF THE CNS (2011)
分享论文
